JP Morgan Upgrades Qiagen on Potential Organic Growth, QIAsymphony Ramp Up | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Citing expected organic growth and a continuing ramp up of QIAsymphony, investment bank JP Morgan today upgraded Qiagen to Overweight.

In a research note, analyst Tycho Peterson upgraded the firm from Neutral and estimated full-year 2012 revenues at $1.25 billion and adjusted earnings per share at $1.01. He maintained a December 2012 price target of $19.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.